Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 17 | 2020 | 744 | 3.240 |
Why?
|
| Metformin | 8 | 2019 | 128 | 3.090 |
Why?
|
| Culturally Competent Care | 2 | 2017 | 12 | 1.250 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 378 | 1.060 |
Why?
|
| Sexual and Gender Minorities | 2 | 2017 | 192 | 0.980 |
Why?
|
| Gynecology | 2 | 2023 | 124 | 0.750 |
Why?
|
| Obstetrics | 2 | 2023 | 120 | 0.740 |
Why?
|
| Glycolysis | 2 | 2017 | 129 | 0.690 |
Why?
|
| BRCA1 Protein | 2 | 2018 | 200 | 0.680 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2016 | 45 | 0.680 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 80 | 0.660 |
Why?
|
| Maternal Health Services | 1 | 2017 | 16 | 0.630 |
Why?
|
| Homosexuality, Female | 1 | 2017 | 15 | 0.620 |
Why?
|
| Fertilization in Vitro | 1 | 2017 | 54 | 0.620 |
Why?
|
| Marriage | 1 | 2017 | 26 | 0.620 |
Why?
|
| Spouses | 1 | 2017 | 33 | 0.620 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 418 | 0.570 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 74 | 0.560 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 20 | 0.550 |
Why?
|
| Epithelial Cells | 2 | 2017 | 669 | 0.530 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 62 | 0.530 |
Why?
|
| Parents | 1 | 2017 | 272 | 0.510 |
Why?
|
| Hyperglycemia | 1 | 2015 | 176 | 0.490 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 95 | 0.480 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 2426 | 0.470 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 1197 | 0.470 |
Why?
|
| Genital Neoplasms, Female | 1 | 2014 | 107 | 0.460 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 193 | 0.450 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 426 | 0.440 |
Why?
|
| Paclitaxel | 1 | 2014 | 460 | 0.440 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 427 | 0.440 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2357 | 0.430 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.410 |
Why?
|
| Female | 24 | 2021 | 44507 | 0.400 |
Why?
|
| Estradiol | 1 | 2011 | 252 | 0.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 378 | 0.370 |
Why?
|
| Adipocytes | 3 | 2020 | 155 | 0.360 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2009 | 6 | 0.360 |
Why?
|
| Norethindrone | 1 | 2009 | 12 | 0.360 |
Why?
|
| Ethinyl Estradiol | 1 | 2009 | 16 | 0.360 |
Why?
|
| Indoles | 1 | 2011 | 318 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1313 | 0.350 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 103 | 0.340 |
Why?
|
| Mice | 12 | 2020 | 11352 | 0.320 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2019 | 151 | 0.320 |
Why?
|
| Vacuum Curettage | 1 | 2007 | 5 | 0.320 |
Why?
|
| Tramadol | 1 | 2007 | 14 | 0.310 |
Why?
|
| Ibuprofen | 1 | 2007 | 28 | 0.310 |
Why?
|
| Models, Biological | 1 | 2015 | 1749 | 0.310 |
Why?
|
| Policy Making | 2 | 2017 | 62 | 0.310 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 2232 | 0.300 |
Why?
|
| Neoplasms | 4 | 2021 | 2897 | 0.290 |
Why?
|
| Humans | 25 | 2023 | 86601 | 0.280 |
Why?
|
| Health Policy | 2 | 2017 | 180 | 0.270 |
Why?
|
| Signal Transduction | 2 | 2015 | 3241 | 0.260 |
Why?
|
| Pain | 1 | 2007 | 391 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 5 | 2014 | 552 | 0.240 |
Why?
|
| Mice, Nude | 4 | 2020 | 790 | 0.230 |
Why?
|
| Animals | 13 | 2020 | 26581 | 0.230 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1578 | 0.230 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1056 | 0.220 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 26 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1373 | 0.210 |
Why?
|
| Faculty, Medical | 1 | 2023 | 178 | 0.200 |
Why?
|
| Blotting, Western | 2 | 2014 | 782 | 0.190 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1204 | 0.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 153 | 0.180 |
Why?
|
| Tumor Burden | 3 | 2020 | 288 | 0.180 |
Why?
|
| Retinal Dehydrogenase | 1 | 2019 | 6 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 592 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 458 | 0.170 |
Why?
|
| Pregnancy | 3 | 2021 | 2893 | 0.170 |
Why?
|
| Stromal Cells | 1 | 2019 | 143 | 0.170 |
Why?
|
| Sphingosine | 1 | 2019 | 71 | 0.170 |
Why?
|
| Lysophospholipids | 1 | 2019 | 63 | 0.170 |
Why?
|
| Carcinogenesis | 1 | 2019 | 195 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 165 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 143 | 0.150 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.150 |
Why?
|
| Cell Survival | 2 | 2020 | 969 | 0.150 |
Why?
|
| Apoptosis | 3 | 2014 | 1683 | 0.150 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 41 | 0.150 |
Why?
|
| Omentum | 2 | 2020 | 71 | 0.150 |
Why?
|
| Chemoprevention | 1 | 2017 | 91 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 266 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2016 | 8475 | 0.140 |
Why?
|
| Carbon | 1 | 2016 | 80 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 1041 | 0.140 |
Why?
|
| Phenformin | 1 | 2015 | 5 | 0.140 |
Why?
|
| Glucose | 2 | 2016 | 638 | 0.140 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2015 | 11 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 639 | 0.140 |
Why?
|
| Aspirin | 1 | 2017 | 156 | 0.140 |
Why?
|
| Ascites | 1 | 2015 | 55 | 0.130 |
Why?
|
| Lactic Acid | 1 | 2015 | 90 | 0.130 |
Why?
|
| Cell Movement | 1 | 2019 | 758 | 0.130 |
Why?
|
| Survival Rate | 2 | 2016 | 1860 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 120 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 192 | 0.130 |
Why?
|
| Lovastatin | 1 | 2014 | 29 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 392 | 0.120 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 1937 | 0.120 |
Why?
|
| Fibronectins | 1 | 2014 | 93 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2014 | 303 | 0.120 |
Why?
|
| Mass Screening | 1 | 2018 | 617 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2014 | 251 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 508 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3092 | 0.110 |
Why?
|
| Mitochondria | 1 | 2016 | 535 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2017 | 7988 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 879 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2015 | 447 | 0.100 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 48 | 0.100 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.100 |
Why?
|
| Anoikis | 1 | 2011 | 7 | 0.100 |
Why?
|
| Coculture Techniques | 3 | 2020 | 164 | 0.100 |
Why?
|
| Prognosis | 2 | 2016 | 3674 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2011 | 248 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 81 | 0.100 |
Why?
|
| Anilides | 1 | 2011 | 47 | 0.100 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 1540 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2013 | 240 | 0.100 |
Why?
|
| Quinolines | 1 | 2011 | 95 | 0.090 |
Why?
|
| Ovary | 1 | 2011 | 257 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 176 | 0.090 |
Why?
|
| fas Receptor | 1 | 2010 | 75 | 0.090 |
Why?
|
| Gonadotropins | 1 | 2009 | 34 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 44 | 0.090 |
Why?
|
| Integrases | 1 | 2009 | 59 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 303 | 0.090 |
Why?
|
| Mutation | 2 | 2018 | 3967 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3636 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 128 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 154 | 0.080 |
Why?
|
| Estrogens | 1 | 2009 | 200 | 0.080 |
Why?
|
| Abortion, Therapeutic | 1 | 2007 | 11 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2014 | 2767 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 2270 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 1379 | 0.070 |
Why?
|
| Aged | 2 | 2016 | 18402 | 0.070 |
Why?
|
| Analgesics | 1 | 2007 | 119 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1464 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3352 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 196 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2009 | 1924 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2887 | 0.060 |
Why?
|
| Middle Aged | 3 | 2021 | 25017 | 0.050 |
Why?
|
| Diethylstilbestrol | 1 | 2021 | 119 | 0.050 |
Why?
|
| Male | 3 | 2021 | 40956 | 0.050 |
Why?
|
| Succinate-CoA Ligases | 1 | 2019 | 3 | 0.050 |
Why?
|
| Prolyl Hydroxylases | 1 | 2019 | 3 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 50 | 0.050 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 22 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 68 | 0.050 |
Why?
|
| Heterografts | 1 | 2020 | 98 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 68 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 674 | 0.040 |
Why?
|
| AC133 Antigen | 1 | 2019 | 9 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 188 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 236 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 49 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 286 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 112 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 153 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 504 | 0.040 |
Why?
|
| Proteomics | 1 | 2020 | 212 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 712 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 1576 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 532 | 0.040 |
Why?
|
| Metabolome | 1 | 2016 | 47 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2016 | 347 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 628 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 461 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1161 | 0.030 |
Why?
|
| Adult | 2 | 2018 | 25640 | 0.030 |
Why?
|
| Integrins | 1 | 2014 | 76 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 87 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 357 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 420 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 232 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 547 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1961 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 391 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 24 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2010 | 49 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 256 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4210 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2010 | 43 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 684 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 127 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 502 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1531 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 589 | 0.020 |
Why?
|
| Obesity | 1 | 2013 | 963 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 735 | 0.010 |
Why?
|